Literature DB >> 16320264

Testing and estimation in flexible group sequential designs with adaptive treatment selection.

Martin Posch1, Franz Koenig, Michael Branson, Werner Brannath, Cornelia Dunger-Baldauf, Peter Bauer.   

Abstract

Integrating selection and confirmation phases into a single trial can expedite the development of new treatments and allows to use all accumulated data in the decision process. In this paper we review adaptive treatment selection based on combination tests and propose overall adjusted p-values and simultaneous confidence intervals. Also point estimation in adaptive trials is considered. The methodology is illustrated in a detailed example based on an actual planned study. Copyright 2005 John Wiley & Sons, Ltd.

Mesh:

Year:  2005        PMID: 16320264     DOI: 10.1002/sim.2389

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  36 in total

1.  The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  BMJ       Date:  2020-06-17

2.  Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment.

Authors:  M Rosenblum; M J Van der Laan
Journal:  Biometrika       Date:  2011-12       Impact factor: 2.445

3.  Response adaptive randomization procedures in seamless phase II/III clinical trials.

Authors:  Hongjian Zhu; Jin Piao; J Jack Lee; Feifang Hu; Lixin Zhang
Journal:  J Biopharm Stat       Date:  2019-08-27       Impact factor: 1.051

4.  Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.

Authors:  Peter Bauer; Frank Bretz; Vladimir Dragalin; Franz König; Gernot Wassmer
Journal:  Stat Med       Date:  2015-03-16       Impact factor: 2.373

5.  Accounting for selection and correlation in the analysis of two-stage genome-wide association studies.

Authors:  David S Robertson; A Toby Prevost; Jack Bowden
Journal:  Biostatistics       Date:  2016-03-18       Impact factor: 5.899

6.  Confidence intervals for the selected population in randomized trials that adapt the population enrolled.

Authors:  Michael Rosenblum
Journal:  Biom J       Date:  2013-04-03       Impact factor: 2.207

7.  Two-stage designs for Phase 2 dose-finding trials.

Authors:  Anastasia Ivanova; Changfu Xiao; Yevgen Tymofyeyev
Journal:  Stat Med       Date:  2012-08-01       Impact factor: 2.373

8.  Unbiased estimation of odds ratios: combining genomewide association scans with replication studies.

Authors:  Jack Bowden; Frank Dudbridge
Journal:  Genet Epidemiol       Date:  2009-07       Impact factor: 2.135

9.  Simultaneous confidence intervals that are compatible with closed testing in adaptive designs.

Authors:  D Magirr; T Jaki; M Posch; F Klinglmueller
Journal:  Biometrika       Date:  2013-12-01       Impact factor: 2.445

10.  The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  Trials       Date:  2020-06-17       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.